HRP20030404A2 - Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity - Google Patents

Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity Download PDF

Info

Publication number
HRP20030404A2
HRP20030404A2 HR20030404A HRP20030404A HRP20030404A2 HR P20030404 A2 HRP20030404 A2 HR P20030404A2 HR 20030404 A HR20030404 A HR 20030404A HR P20030404 A HRP20030404 A HR P20030404A HR P20030404 A2 HRP20030404 A2 HR P20030404A2
Authority
HR
Croatia
Prior art keywords
disorder
gaba
use according
compound
disease
Prior art date
Application number
HR20030404A
Other languages
English (en)
Croatian (hr)
Inventor
Ebert Bjarke
Peter Høngaard Andersen
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8159857&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20030404(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of HRP20030404A2 publication Critical patent/HRP20030404A2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HR20030404A 2000-11-20 2001-11-20 Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity HRP20030404A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200001743 2000-11-20
PCT/DK2001/000773 WO2002040009A1 (en) 2000-11-20 2001-11-20 Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity

Publications (1)

Publication Number Publication Date
HRP20030404A2 true HRP20030404A2 (en) 2005-04-30

Family

ID=8159857

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030404A HRP20030404A2 (en) 2000-11-20 2001-11-20 Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity

Country Status (33)

Country Link
US (2) US20040024038A1 (de)
EP (1) EP1337247B1 (de)
JP (1) JP4152186B2 (de)
KR (1) KR100865651B1 (de)
CN (1) CN1318027C (de)
AR (1) AR031473A1 (de)
AT (1) ATE336242T1 (de)
AU (2) AU2351402A (de)
BG (1) BG107909A (de)
BR (1) BR0115668A (de)
CA (1) CA2429220C (de)
CY (1) CY1106209T1 (de)
CZ (1) CZ20031383A3 (de)
DE (1) DE60122368T2 (de)
DK (1) DK1337247T3 (de)
EA (1) EA007287B1 (de)
ES (1) ES2266308T3 (de)
HR (1) HRP20030404A2 (de)
HU (1) HUP0400505A3 (de)
IL (1) IL155587A0 (de)
IS (1) IS2427B (de)
ME (1) MEP6408A (de)
MX (1) MXPA03004349A (de)
NO (1) NO20032271L (de)
NZ (1) NZ525520A (de)
PL (1) PL361051A1 (de)
PT (1) PT1337247E (de)
SI (1) SI1337247T1 (de)
SK (1) SK7682003A3 (de)
UA (1) UA77403C2 (de)
WO (1) WO2002040009A1 (de)
YU (1) YU39003A (de)
ZA (1) ZA200303289B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
DE50214447D1 (de) * 2001-11-26 2010-07-01 Finzelberg Gmbh & Co Kg Ingwer-extraktzubereitung
DK1641456T3 (da) * 2003-06-25 2010-06-21 Lundbeck & Co As H Gaboxadol til behandling af depression og andre affektive lidelser
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
JP2008504306A (ja) * 2004-06-29 2008-02-14 ハー・ルンドベック・アクチエゼルスカベット 神経因性疼痛、線維筋痛症または慢性関節リウマチの治療
WO2006012563A2 (en) * 2004-07-23 2006-02-02 The Regents Of The University Of California Method for the treatment and diagnosis of certain psychiatric disorders related to the menstrual cycle
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
WO2006083682A2 (en) 2005-01-28 2006-08-10 H.Lundbeck A/S Polymorphic forms of a gabaa agonist
US20070122507A1 (en) * 2005-05-26 2007-05-31 Palu Afa K Histone deacetylase and tumor necrosis factor converting enzyme inhibition
US8280978B2 (en) * 2006-12-29 2012-10-02 Prodea Systems, Inc. Demarcation between service provider and user in multi-services gateway device at user premises
US20080280983A1 (en) * 2007-05-09 2008-11-13 Cenerx Biopharma Methods of treating rett syndrome
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
CN103547240B (zh) * 2011-06-16 2016-03-30 索雷斯生命科学公司 用于人类自主神经系统的平衡和维持健康的系统和方法
RU2496496C1 (ru) * 2012-10-04 2013-10-27 Исаак Григорьевич Гитлин Фармацевтическая композиция, обладающая гамк-ергической активностью
IL256912B2 (en) 2015-07-17 2024-01-01 Ovid Therapeutics Inc Methods of treating developmental disorders with gaboxadol
EP4233861A3 (de) * 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Zusammensetzungen zur behandlung von essentiellem tremor
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
KR102049522B1 (ko) * 2018-06-05 2019-11-27 충남대학교산학협력단 Gaba를 유효성분으로 하는 살모넬라 감염질환의 예방 및 치료용 조성물
KR102049526B1 (ko) * 2018-06-05 2019-11-27 충남대학교산학협력단 Gaba를 유효성분으로 하는 항결핵 약학 조성물
MX2021003302A (es) 2018-09-20 2021-05-13 Ovid Therapeutics Inc Uso de gaboxadol para el tratamiento del sindrome de tourette, los tics y la tartamudez.
US11123332B2 (en) 2018-11-21 2021-09-21 Certego Therapeutics Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression
EP3880201A4 (de) 2018-12-17 2022-07-27 Ovid Therapeutics Inc. Verwendung von gaboxadol zur behandlung von nicht-24-stündiger schlaf-wach-störung
KR20220009954A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
EP4051272A4 (de) 2019-12-18 2023-01-04 Ovid Therapeutics Inc. Gaboxadol zur therapeutischen behandlung von 1p36-deletionssyndrom
MX2022014599A (es) 2020-05-20 2022-12-16 Certego Therapeutics Inc Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.
CN114404437A (zh) * 2022-03-15 2022-04-29 山东中医药大学 没食子酰芍药苷在制备gabaa受体抑制剂中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4362731A (en) * 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
EP0603312A4 (de) * 1991-09-13 1995-06-07 Cocensys Inc Neuer gaba a-rezeptor mit steroidbindungsstellen.
US5206415A (en) * 1991-12-20 1993-04-27 Washington University Tricyclic steroid analogs
CZ300694A3 (en) * 1993-12-02 1996-05-15 Akzo Nobel Nv Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof
FI972202L (fi) * 1994-11-23 1997-07-17 Cocensys Inc Androstaanit ja pregnaanit GABA-reseptoreiden allosteeriseen muunteluun
US5776959A (en) * 1995-06-05 1998-07-07 Washington University Anticonvulsant and anxiolytic lactam and thiolactam derivatives
RU2194712C2 (ru) * 1995-06-06 2002-12-20 Коукенсис, Инк. НЕЙРОАКТИВНЫЕ СТЕРОИДЫ, ФАРМАЦЕВТИЧЕСКИЙ ПРЕПАРАТ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАЗЛИЧНЫХ НАРУШЕНИЙ, СПОСОБ ИНДУКЦИИ СНА И СПОСОБ ИНДУКЦИИ АНЕСТЕЗИИ С ИХ ИСПОЛЬЗОВАНИЕМ, СПОСОБ МОДУЛИРОВАНИЯ КОМПЛЕКСА РЕЦЕПТОР ГАМКa-ХЛОРИДНЫЙ ИОНОФОР
IT1290003B1 (it) * 1997-03-03 1998-10-19 Angelini Ricerche Spa Uso di pivagabina per preparare composizioni farmaceutiche
GB9801208D0 (en) * 1998-01-21 1998-03-18 Merck Sharp & Dohme Therapeutic agents
DE69909486T2 (de) * 1998-07-22 2004-05-27 Akzo Nobel N.V. Phenylester-derivate von alpha-aminosäuren
CN1607201A (zh) * 1999-12-08 2005-04-20 沃尼尔·朗伯公司 立体选择性地合成环状氨基酸的方法

Also Published As

Publication number Publication date
YU39003A (sh) 2006-05-25
EA200300594A1 (ru) 2003-10-30
EP1337247A1 (de) 2003-08-27
JP4152186B2 (ja) 2008-09-17
NZ525520A (en) 2005-04-29
IS6803A (is) 2003-04-30
JP2004513921A (ja) 2004-05-13
CN1592616A (zh) 2005-03-09
BR0115668A (pt) 2003-09-02
KR100865651B1 (ko) 2008-10-29
MXPA03004349A (es) 2003-08-19
BG107909A (bg) 2004-08-31
DE60122368D1 (de) 2006-09-28
SI1337247T1 (sl) 2006-12-31
US20090143435A1 (en) 2009-06-04
IS2427B (is) 2008-10-15
CA2429220C (en) 2009-09-15
ZA200303289B (en) 2005-07-27
EP1337247B1 (de) 2006-08-16
CN1318027C (zh) 2007-05-30
DE60122368T2 (de) 2007-08-09
CA2429220A1 (en) 2002-05-23
KR20030065517A (ko) 2003-08-06
MEP6408A (xx) 2010-02-10
AU2351402A (en) 2002-05-27
EA007287B1 (ru) 2006-08-25
DK1337247T3 (da) 2006-12-04
NO20032271D0 (no) 2003-05-20
ES2266308T3 (es) 2007-03-01
AU2002223514B2 (en) 2006-11-30
UA77403C2 (en) 2006-12-15
HUP0400505A2 (hu) 2004-07-28
HK1075010A1 (en) 2005-12-02
AR031473A1 (es) 2003-09-24
NO20032271L (no) 2003-05-20
ATE336242T1 (de) 2006-09-15
CY1106209T1 (el) 2011-06-08
US20040024038A1 (en) 2004-02-05
CZ20031383A3 (cs) 2003-08-13
PL361051A1 (en) 2004-09-20
WO2002040009A1 (en) 2002-05-23
HUP0400505A3 (en) 2008-08-28
SK7682003A3 (en) 2003-10-07
IL155587A0 (en) 2003-11-23
PT1337247E (pt) 2006-11-30

Similar Documents

Publication Publication Date Title
HRP20030404A2 (en) Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity
AU2002223514A1 (en) Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity
EP1839657A2 (de) Verfahren zur Behandlung vaskulärer Kopfschmerzen
Zhang et al. Non-opioid-dependent anti-inflammatory effects of low frequency electroacupuncture
AT9895U1 (de) Verfahren zur behandlung von viszeralem schmerz
ES2394639T3 (es) Esteroides de pregnano para utilización en el tratamiento de trastornos del CNS
CN114010641A (zh) 用于治疗神经病症的方法
CZ20032172A3 (cs) Farmaceutické prostředky pro léčení demyelinačních onemocnění
Hamann et al. Effects of striatal injections of GABAA receptor agonists and antagonists in a genetic animal model of paroxysmal dystonia
MXPA01012794A (es) Composicion farmaceutica para la terapia de sintomas del tracto urinario inferior.
Jiang et al. Ketamine anaesthesia interferes with the quinolinic acid-induced lesion in a rat model of Huntington's disease
Kontani et al. A method for producing overactive bladder in the rat and investigation of the effects of GABAergic receptor agonists and glutamatergic receptor antagonists on the cystometrogram
Bucci et al. The central-nervous-system toxicity of long-term oral administration of L-tryptophan to porto-caval-shunted rats
HK1075010B (en) Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity
HK40068517A (en) Methods for treating neurologic disorders
BR122025019564A2 (pt) Dispersão seca por pulverização, composição para sua formulação e método de fabricação da mesma, forma de dosagem sólida e seu método de fabricação, e uso de um inibidor de piridazinona trpc5 para tratar dor, ansiedade ou depressão
JPS6092216A (ja) 抗リウマチ剤
Wang Neuropharmacological and kinetic correlates of antiepileptic drugs in an animal model of status epilepticus
HK1107933B (en) Use of oxycodone for treating visceral pain

Legal Events

Date Code Title Description
ODRP Renewal fee for the maintenance of a patent

Payment date: 20050407

Year of fee payment: 4

A1OB Publication of a patent application
OBST Application withdrawn